COMMUNIQUÉS West-GlobeNewswire

Nicox : Demande d’autorisation de mise sur le marché de NCX 470 soumise aux Etats-Unis par Kowa, avec un paiement d’étape de 3 millions d’euros associé
01/07/2026
Communiqué de presse Nicox : Demande d’autorisation de mise sur le marché de NCX 470 soumise aux Etats-Unis par Kowa, avec un paiement d’étape de 3 millions d’euros associé La demande d’autorisation de mise sur le [...]
Nicox’s NCX 470 New Drug Application Submitted in the United States by Kowa, with Associated €3 million Milestone Payment
01/07/2026
Press Release Nicox’s NCX 470 New Drug Application Submitted in the United States by Kowa, with Associated €3 million Milestone Payment NCX 470 New Drug Application (NDA) submitted to the U.S. Food and Drug [...]
Eurobio Scientific finalizes the acquisition of CareDX’s transplant Lab Product division
01/07/2026
EUROBIO SCIENTIFIC FINALIZES THE ACQUISITION OF CAREDX’s TRANSPLANT LAB PRODUCT DIVISION Acceleration of Eurobio’s strategic plan to become an in-vitro molecular diagnostics (“IVD”) leader Creation of a global leading [...]
Eurobio Scientific finalise l'acquisition de la division « Lab Products » de CareDX dédiée à la transplantation
01/07/2026
EUROBIO SCIENTIFIC FINALISE L'ACQUISITION DE LA DIVISION « LAB PRODUCTS 1 » DE CAREDX DÉDIÉE À LA TRANSPLANTATION Accélération du plan stratégique d’Eurobio visant à devenir un leader du diagnostic moléculaire in vitro [...]
AB Science annonce le succès d’un placement privé de 2,3 millions d’euros
01/07/2026
COMMUNIQUE DE PRESSE AB SCIENCE ANNONCE LE SUCCES D’UN PLACEMENT PRIVE DE 2,3 MILLIONS D’EUROS Paris, 1 er juillet 2026, 8h AB Science S.A. (la “ Société ” ou “ AB Science ”, Euronext – FR0010557264 – AB) annonce [...]
AB Science announces the successful completion of a EUR 2.3 million private placement
01/07/2026
PRESS RELEASE AB SCIENCE ANNOUNCES THE SUCCESSFUL COMPLETION OF A EUR 2.3 MILLION PRIVATE PLACEMENT Paris, July 1 st , 2026, 8am AB Science S.A. (the “ Company ” or “ AB Science ”, Euronext – FR0010557264 – AB) [...]
Aptose Biosciences Announces Completion of Acquisition by Hanmi Pharmaceutical
01/07/2026
SAN DIEGO and TORONTO, June 30, 2026 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS and OTC: APTOF), a clinical-stage precision oncology company developing a tuspetinib (TUS)-based [...]
Cadrenal Therapeutics Announces up to $8.8 Million Private Placement Priced At-The-Market Under Nasdaq Rules
01/07/2026
$3 million upfront with up to approximately $5.8 million of potential additional gross proceeds upon the exercise in full of warrants Net proceeds anticipated to extend cash runway into first quarter of 2027; if [...]
Mesoblast Receives BLA Filing Number and Requests Modular Review for Rexlemestrocel-L in Patients with End-Stage Heart Failure and LVADs
01/07/2026
NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has received a Biologics License [...]
Pelthos Therapeutics Added to Russell 3000E™ Growth Benchmark, Russell Microcap® and Russell Microcap® Growth Benchmark Indexes
30/06/2026
DURHAM, N.C., June 30, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs, (“ [...]
Avicanna Announces Promotion of Nick Hilborn CPA CA to Chief Financial Officer
30/06/2026
TORONTO, June 30, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“ Avicanna ” or “ Company ) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of [...]
Cronos Announces Appointment of ATB Cormark as its Broker for Share Repurchases in Canada
30/06/2026
TORONTO, June 30, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (“Cronos” or the “Company”) (NASDAQ: CRON) (TSX: CRON), an innovative global cannabis company, announced today that it has appointed ATB Capital Markets Corp [...]
XTL Completed the Acquisition of Psyga Bio Ltd.
30/06/2026
expands its IP portfolio to clinical-stage biopharmaceutical assets XTL Biopharmaceuticals (XTL) Completes the Acquisition of Psyga Bio and Establishes Psychedelic Biotechnology Platform At a historic juncture and with [...]
Abivax Announces Launch of Public Offering of American Depositary Shares
30/06/2026
Abivax Announces Launch of Public Offering of American Depositary Shares PARIS, France – June 30, 2026 – 10:45 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“ Abivax ” or the “ Company ”), [...]
Abivax annonce le lancement d’une offre au public d’American Depositary Shares
30/06/2026
Abivax annonce le lancement d’une offre au public d’American Depositary Shares PARIS, France – 30 juin 2026 – 22h45 CEST – Abivax SA (Euronext Paris : FR0012333284 – ABVX) (« Abivax » ou la « Société »), une société de [...]
ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules
30/06/2026
SOUTH SAN FRANCISCO, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology," Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat [...]
Liminatus Pharma Amends Definitive Merger Agreement with InnocsAI to Expand Oncology Cell Therapy Pipeline
30/06/2026
Transaction Expected to Close July 2, 2026 FULLERTON, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (Nasdaq: LIMN) ("Liminatus" or the "Company"), a biotechnology company developing innovative cancer [...]
Resmed to Report Fourth Quarter Fiscal 2026 Earnings on August 6, 2026
30/06/2026
SAN DIEGO, June 30, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the fourth quarter of fiscal year 2026 on Thursday, August 6, 2026, [...]
Result of Annual General Meeting
30/06/2026
June 30, 2026 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Result of Annual General Meeting Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) (“Biodexa” or “the Company”), a clinical stage biopharmaceutical company [...]

Pages